Replies to post #104310 on Amarantus Bioscience Holdings Inc (AMBS)

[Sir Francelote]

My hunch is it'll be Janssen Pharmaceuticals; not only because AMBS was selected to move into their QB3 labs last year, but also given that Janssen announced early this year that it would be targeting unmet global health needs:

Janssen Announces New Group Targeting Unmet Global Health Needs

The Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to addressing and solving the most important unmet medical needs of our time, including oncology (e.g., multiple myeloma and prostate cancer), immunology (e.g., rheumatoid arthritis, inflammatory bowel disease and psoriasis), neuroscience (e.g., schizophrenia, dementia and pain), infectious disease (e.g., HIV/AIDS, Hepatitis C and tuberculosis), and cardiovascular and metabolic diseases (e.g., diabetes).

Additionally, Janssen Pharmaceutical, being a J&J company, has offices all over Europe, Asia, and the Americas.